Alpha-1-adrenergic receptor agonist therapy
Presented herein, inter alia, are novel methods of treating heart diseases.
1. A method of treating cardiomyopathy in a patient in need of such treatment, said method comprising administering a therapeutically or prophylactically effective amount of dabuzalgron, a pharmaceutically acceptable salt, or prodrug thereof to said patient.
2. The method of claim 1 , wherein said cardiomyopathy is associated with anthracycline administration, hypertension, heart valve disease, myocardial ischemia, or heart failure.
3. The method of claim 1 , wherein said cardiomyopathy is associated with anthracycline administration.
4. The method of claim 3 , wherein said anthracycline is doxorubicin, daunorubicin, epirubicin, idarubucin, adriamycin, or valrubicin.
5. The method of claim 3 , wherein the dabuzalgron is co-administered with the anthracycline.
6. The method of claim 3 , wherein the dabuzalgron is administered before administration of the anthracycline.
7. The method of claim 3 , wherein the dabuzalgron is administered after administration of the anthracycline.
8. The method of claim 1 , wherein said patient's blood pressure does not increase as a result of said administration.
9. The method of claim 1 , wherein said patient's blood pressure increases by an amount equal to or less than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mmHg as a result of said administration.
10. The method of claim 9 , wherein said blood pressure is a systolic blood pressure.
11. The method of claim 1 , wherein said effective amount is between about 0.001 and 1000, 0.1 and 100, 1 and 50, or 5 and 25 micrograms/kilogram patient weight.
12. The method of claim 1 , wherein said effective amount is about 20 micrograms/kilogram patient weight.
13. The method of claim 1 , wherein said effective amount is 20 micrograms/kilogram patient weight.
14. The method of claim 1 , wherein said effective amount is the total amount administered to said patient in a day.
15. The method of claim 1 , wherein said administering is parenteral, intravenous, intraarterial, buccal, sublingual, oral, peroral, transdermal, or nasal.